- $953.67m
- $964.68m
- $713.14m
- 36
- 67
- 73
- 61
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.7 | ||
| Price to Tang. Book | 38.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.34 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -7.58% | ||
| Return on Equity | -3.86% | ||
| Operating Margin | -21.32% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,435.41 | 1,774.72 | 1,004.2 | 863.5 | 713.14 | 662.51 | 716.27 | -4.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Directors
- Phillip Frost CHM (84)
- Jane Hsiao VCH (74)
- Adam Logal CFO (43)
- Jon Cohen CEX (67)
- Charles Bishop CEX (69)
- Tony Cruz CEX (67)
- Geoff Monk CEX (65)
- Katherine Stueland CEX (45)
- Steven Rubin EVP (61)
- Richard Krasno IND (79)
- Prem Lachman IND (60)
- Roger Medel IND (74)
- John Paganelli IND (86)
- Richard Pfenniger IND (65)
- Alice Yu IND (77)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 18th, 1991
- Public Since
- November 2nd, 1995
- No. of Shareholders
- 346
- No. of Employees
- 2,997
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 671,601,520
- Address
- 4400 Biscayne Blvd., MIAMI, 33137
- Web
- https://www.opko.com/
- Phone
- +1 3055754181
- Contact
- Yvonne Briggs
- Auditors
- Ernst & Young LLP
Upcoming Events for OPK
Q1 2025 OPKO Health Inc Earnings Release
Q1 2025 OPKO Health Inc Earnings Call
Q2 2025 OPKO Health Inc Earnings Release
Similar to OPK
Acadia Healthcare
NASDAQ Global Select Market
Addus HomeCare
NASDAQ Global Select Market
Alignment Healthcare
NASDAQ Global Select Market
Amedisys
NASDAQ Global Select Market
Aveanna Healthcare Holdings
NASDAQ Global Select Market
FAQ
What is the Opko Health share price?
As of Today at 22:27 UTC, shares in Opko Health are trading at $1.42. This share price information is delayed by 15 minutes.
How has the Opko Health share price performed this year?
Shares in Opko Health last closed at $1.42 and the price had moved by +13.6% over the past 365 days. In terms of relative price strength the Opko Health share price has outperformed the S&P500 Index by +6.82% over the past year.
What are the analyst and broker recommendations for Opko Health?
The overall consensus recommendation for Opko Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Opko Health dividend yield?
Opko Health does not currently pay a dividend.
Does Opko Health pay a dividend?
Opko Health does not currently pay a dividend.
When does Opko Health next pay dividends?
Opko Health does not currently pay a dividend.
How do I buy Opko Health shares?
To buy shares in Opko Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Opko Health?
As of the previous close price of $1.42, shares in Opko Health had a market capitalisation of $953.67m.
Where are Opko Health shares listed?
Here are the trading details for Opko Health:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: OPK
What kind of share is Opko Health?
Based on an overall assessment of its quality, value and momentum Opko Health is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Opko Health share price forecast for 2025?
The analyst consensus target price for shares in Opko Health is $3.99. That is 180.99% above the last closing price of $1.42.
Analysts covering Opko Health currently have a consensus Earnings Per Share (EPS) forecast of -$0.30 for the next financial year.
Find out moreWhat is the trend in the Opko Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Opko Health. Over the past six months, its share price has outperformed the S&P500 Index by +7.04%.
As of the last closing price of $1.42, shares in Opko Health were trading -8.32% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Opko Health PE Ratio?
The Opko Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.42.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Opko Health?
Opko Health's management team is headed by:
- Phillip Frost - CHM
- Jane Hsiao - VCH
- Adam Logal - CFO
- Jon Cohen - CEX
- Charles Bishop - CEX
- Tony Cruz - CEX
- Geoff Monk - CEX
- Katherine Stueland - CEX
- Steven Rubin - EVP
- Richard Krasno - IND
- Prem Lachman - IND
- Roger Medel - IND
- John Paganelli - IND
- Richard Pfenniger - IND
- Alice Yu - IND